Figure 6.

Effects of pravastatin and anti-interleukin 17 (IL-17) antibody on airway hyper-responsiveness (AHR) and allergic airway inflammation in a mouse model of obesity-related asthma. High-fat diet ovalbumin (HFD-OVA) mice were treated with pravastatin + anti-IL-17 antibody. (A) AHR measured as respiratory resistance 24 hours after the final OVA challenge. (B) Inflammatory cell infiltration in the bronchoalveolar lavage fluid (BALF) 24 hours after the final OVA challenge. (C) Paraffin-embedded lung tissue sections stained with H&E and periodic acid-Schiff (PAS) (×200). Results are expressed as mean ± SEM (n = 5 to 9 per group). CON, control. ^ap < 0.05, ^bp < 0.001 vs. control group, ^cp < 0.05, ^dp < 0.01, ^ep < 0.001 vs. HFD-OVA group, and ^fp < 0.05 vs. HFD-OVA + anti-IL-17 antibody group.